Clinical trial
Nonmyeloablative Preparative Regimen Using Mylotarg for Patients With High Risk…
NCT00038805 · M.D. Anderson Cancer Center, Other · Terminated
Key facts
| NCT number | NCT00038805 |
|---|---|
| Title | Nonmyeloablative Preparative Regimen Using Mylotarg for Patients With High Risk Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Chronic Myeloid Leukemia (CML) and Myelodysplastic Syndrome (MDS) |
| Official title | Allogeneic Stem Cell Transplantation Using Mylotarg (CMA-676) Plus Nonmyeloablative Chemotherapy in Older or Medically Infirm Patients With High-Risk Acute Leukemia (ALL), Chronic Myelogenous Leukemia (CML) or Myelodysplastic Syndrome (MDS) |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | Wyeth is now a wholly owned subsidiary of Pfizer Industry |
| Status | Terminated |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Leukemia |
| Intervention type | Drug |
| Interventions | Mylotarg |
| Enrollment | 3 |
| Start date | May 1, 2001 |
| Primary completion | Nov 1, 2004 |
| Completion | Nov 1, 2004 |
| First posted | Jun 7, 2002 |
| Last update posted | Oct 31, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: